Magazine article Clinical Psychiatry News

Maternal Paroxetine Unrelated to Cardiac Malformations

Magazine article Clinical Psychiatry News

Maternal Paroxetine Unrelated to Cardiac Malformations

Article excerpt

MONTEREY, CALIF. -- There is no statistically significant association between paroxetine usage during the first trimester of pregnancy and an increased risk of cardiac malformations in the infants, according to a meta-analysis of nine studies.

A selective serotonin reuptake inhibitor frequently prescribed for depression and anxiety, paroxetine (Paxil) was the subject of a 2005 warning by the Food and Drug Administration, Health Canada, and its manufacturer referencing unpublished findings of cardiac malformations in infants exposed during the first trimester of pregnancy.

Several other studies appeared to confirm these findings, Lisa O'Brien reported in a poster session at the annual meeting of the Teratology Society. And a meta-analysis published in 2007 that included all of the studies published up until that time found that first-trimester paroxetine presented a modest increased risk of cardiac malformations (Clin. Ther. 2007;29:918-26).

Since then, however, several more studies have been published. Ms. O'Brien of the Hospital for Sick Children, Toronto, and her colleagues identified a total of nine studies that could be included in their analysis--six cohort studies and three case-control studies--which they analyzed separately. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.